Author:
Pączkowska E.,Smukowska D.,Tratkiewicz E.,Białasiewicz P.
Reference13 articles.
1. European Pharmacopoeia, EDQM, 2011. http://www.edqm.eu
2. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, London, 2009. Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) Including the Requirements for Demonstration of Therapeutic Equivalence between Two Inhaled Products for Use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Adults and for Use in the Treatment of Asthma in Children And Adolescents
3. The physico-chemical properties of salmeterol and fluticasone propionate in different solvent environments
4. Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (salmeterol xinafoate) and a pharmacologically active steroid (fluticasone propionate)